drug

APN1125

as of 2026-07-01
Add to landscapeMonitor thisCompare thisAsk about this
at a glance
small molecule
Pre-approval / investigational in the US
Developed by CoMentis
2 trials in the graph
Synthesized from structured facts only — each point cited above.

Mechanism & identity

Modality
small molecule

Indications

Investigational (via trials)
SchizophreniaSchizophrenia

Trials

2
Safety, Tolerability, and Pharmacokinetics of APN1125 in Subjects With Schizophrenia
NCT02724917Phase 1, Phase 2Suspended
Safety, Tolerability, and Pharmacokinetics of Single Doses of APN1125 in Healthy Normal Subjects
NCT02331433Phase 1Completed

KOLs & investigators

2
David P Walling, PhDKOL score 17
David Han, MD

Facts & assertions

0 sourced
No assertions recorded for this entity.
relationships
The graph out of here
developer
CoMentis
company
trial
Safety, Tolerability, and Pharmacokinetics of APN1125 in Subjects With Schizophrenia
PHASE1, PHASE2
trial
Safety, Tolerability, and Pharmacokinetics of Single Doses of APN1125 in Healthy Normal Subjects
PHASE1
trial
indication
Schizophrenia
indication
Schizophrenia
indication
KOL
David P Walling, PhD
KOL score 17
person
David Han, MD
KOL score —
person